New hope for advanced breast cancer patients who stopped responding to standard therapy
NCT ID NCT07366840
First seen Jan 27, 2026 · Last updated Apr 29, 2026 · Updated 9 times
Summary
This study tests a new drug combination (RC48 plus chemotherapy) in 268 women with advanced HER2-positive breast cancer whose disease worsened or who couldn't tolerate a prior antibody-drug conjugate treatment. The goal is to see if the new combo works better than the current standard treatment (trastuzumab or inetetamab plus chemo) at delaying cancer growth. Participants must have had no more than 3 prior treatments for advanced disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.